Dr. Lohr Interview:
Dr. Crabtree Interview:
As PharmaCyte Biotech heads into the final preparations for its Phase 2b clinical trial in advanced pancreatic cancer, the company hosted a medical and scientific discussion of our therapy for advanced pancreatic cancer among top oncologist investigators who have expressed interest in PharmaCyte’s technology and participation in the Phase 2b clinical trial. Below you will find the 5 presentations that were delivered to those invited oncologists. After Dr. Manuel Hidalgo, a member of PharmaCyte’s medical and scientific advisory board, completed his presentation of the design of the upcoming Phase 2b clinical trial, an hour-long discussion took place between those invited oncologists and those representing PharmaCyte Biotech; Dr. Matthias Löhr, Dr. Manuel Hidalgo, Prof. Dr. Walter H. Günzburg, and Dr. Brian Salmons.